Gemtuzumab ozogamicin: An anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia

Expert Opinion on Biological Therapy

Volumn 8, Issue 4, 2008, Pages 527-540

  Stasi, Roberto ^a  

^a REGINA APOSTOLORUM HOSPITAL   (Italy)

Author keywords

Acute myeloid leukaemia; Acute promyelocytic leukaemia; Gemtuzumab ozogamicin; Immunoconjugate; Monoclonal antibodies

Indexed keywords

ANTIBODY CONJUGATE; CD33 ANTIGEN; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; TOPOTECAN; AMINOGLYCOSIDE; ANTINEOPLASTIC AGENT; DIFFERENTIATION ANTIGEN; GEMTUZUMAB; IMMUNOTOXIN; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; AREA UNDER THE CURVE; CHILL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOTENSION; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MUCOSA INFLAMMATION; PROMYELOCYTIC LEUKEMIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SEPSIS; SIDE EFFECT; STEM CELL TRANSPLANTATION; VEIN OCCLUSION; ADULT; AGED; IMMUNOLOGY; MIDDLE AGED; MORTALITY; RECURRENT DISEASE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTOXINS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; RECURRENCE; TREATMENT OUTCOME;

EID: 42149094530     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.8.4.527     Document Type: Review

References (78)

1. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999;341(14):1051-62
2. Deschler B, Lubbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer 2006;107(9):2099-107
3. Estey E, Dohner H. Acute myeloid leukaemia. Lancet 2006;368(9550):1894- 907
4. Bishop JF, Lowenthal RM, Joshua D, et al. Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group. Blood 1990;75(1):27-32
5. Bishop JF, Matthews JP, Young GA, et al. Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group, Leuk Lymphoma 1998;28(3-4):315-27
6. Stone RM. The difficult problem of acute myeloid leukemia in the older adult. CA Cancer J Clin 2002;52(6):363-71
7. Burnett AK, Knapper S. Targeting treatment in AML. Hematology Am Soc Hematol Educ Program 2007;2007:429-34
8. Feldman EJ, Brandwein J, Stone R, et al. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol 2005;23(18):4110-6
9. Hamann PR, Hinman LM, Hollander I, et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem 2002;13(1):47-58
10. I. J Am Chem Soc 1987;109:3464-6
11. Zein N, Sinha AM, McGahren WJ, Ellestad GA. Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science 1988;240(4856):1198-201
12. Linenberger ML. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia 2005;19(2):176-82
13. Bernstein ID. Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate. Leukemia 2000;14(3):474-5
14. van Der Velden VH, te Marvelde JG, Hoogeveen PG, et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotatg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 2001;97(10):3197-204
15. Walter RB, Raden BW, Kamikura DM, et al. Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity. Blood 2005;105(3):1295-302
16. Linenberger ML, Hong T, Flowers D, et al. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood 2001;98(4):988-94
17. Walter RB, Raden BW, Cronk MR, et al. The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin. Blood 2004;103(11):4276-84
18. Walter RB, Gooley TA, van der Velden VH, et al. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood 2007;109(10):4168-70 • This study shows that AML blasts of responders to gemtuzumab ozogamicin have a significandy higher mean CD33 level and lower P-glycoprotein activity (Pgp) compared with nonresponders. CD33 expression and Pgp activity are inversely correlated.
19. Rutella S, Bonanno G, Procoli A, et al. Granulocyte colony-stimulating factor enhances the in vitro cytotoxicity of gemtuzumab ozogamicin against acute myeloid leukemia cell lines and primary blast cells. Exp Hematol 2006;34(1):54-65
20. ten Cate B, Samplonius DF, Bijma T, et al. The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells. Leukemia 2007;21(2):248-52
21. van det Velden VH, Boeckx N, Jedema I, et al. High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients. Leukemia 2004;18(5):983-8
22. Dowell JA, Korth-Bradley J, Liu H, et al. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J Clin Pharmacol 2001;41(11):1206-14
23. Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001;7(6):1490-6
24. Korth-Bradley JM, Dowell JA, King SP, et al. Impact of age and gender on the pharmacokinetics of gemtuzumab ozogamicin. Pharmacotherapy 2001;21(10):1175-80
25. Buckwaker M, Dowell JA, Korth-Bradley J, et al. Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia. J Clin Pharmacol 2004;44(8):873-80
26. Sievers EL, Appelbaum FR, Spielberger RT, et al. Selective ablation of acute myeloid leukemia using antibody-targered chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 1999;93(11):3678-84
27. Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001;19(13):3244-54
28. Larson RA, Boogaerts M, Estey E, et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia 2002;16(9):1627-36
29. Larson RA, Sievers EL, Stadtmauer EA, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 2005;104(7):1442-52 •• This study details the final results of the 3 pivotal Phase II studies of gemtuzumab ozogamicin (GO) in patients with CD33-positive AML in first recurrence.
30. Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990;8(5):813-9
31. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003;21(24):4642-9
32. Roboz GJ, Knovich MA, Bayer RL, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia. Leuk Lymphoma 2002;43(10):1951-5
33. Estey EH, Thall PF, Giles FJ, et al. Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood 2002;99(12):4343-9
34. Amadori S, Suciu S, Stasi R, et al. Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups. Leukemia 2005;19(10):1768-73
35. Nabhan C, Rundhaugen LM, Riley MB, et al. Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older. Leuk Res 2005;29(1):53-7
36. 2 on days 1, 4 and 7 for one course) of GO may be equally efficient and better tolerated than standard doses.
37. van der Heiden PL, Jedema I, Willemze R, Barge RM. Efficacy and toxicity of gemtuzumab ozogamicin in patients with acute myeloid leukemia. Eur J Haematol 2006;76(5):409-13
38. Piccaluga PP, Martinelli G, Rondoni M, et al. Gemtuzumab ozogamicin for relapsed and refracrory acute myeloid leukemia and myeloid sarcomas. Leuk Lymphoma 2004;45(9):1791-5
39. Zwaan CM, Reinhardt D, Corbacioglu S, et al. Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis. Blood 2003:101(10):3868-71
40. Reinhardt D, Diekamp S, Fleischhack G, et al. Gemtuzumab ozogamicin (Mylotarg) in children with refractory or relapsed acute myeloid leukemia. Onkologie 2004;27(3):269-72
41. Brethon B, Auvrignon A, Galambrun C, et al. Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg) in children with relapsed/refracrory myeloid leukemia. BMC Cancer 2006;6:172. Published online 28 June 2006, doi:10.1186/1471-2407-6-172
42. Arceci RJ, Sande J, Lange B, et al. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. Blood 2005;106(4):1183-8
43. Cortes J, Tsimberidou AM, Alvarez R, et al. Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia. Cancer Chemother Pharmacol 2002;50(6):497-500
44. Alvarado Y, Tsimberidou A, Kantarjian H, et al. Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia. Cancer Chemother Pharmacol 2003;51(1):87-90
45. Apostolidou E, Cortes J, Tsimberidou A, et al. Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia. Leuk Res 2003;27(10):887-91
46. Tsimberidou A, Estey E, Cortes J, et al. Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Cancer 2003;97(6):1481-7
47. Tsimberidou A, Cortes J, Thomas D, et al. Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leuk Res 2003;27(10):893-7
48. Kell WJ, Burnett AK, Chopra R, et al. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood 2003;102(13):4277-83
49. Amadori S, Suciu S, Willemze R, et al. Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups. Haematologica 2004;89(8):950-6
50. Chevallier P, Roland V, Mahe B, et al. Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leuk Res 2005;29(9):1003-7
51. Clavio M, Vignolo L, Albarello A, et al. Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients. Br J Haematol 2007;138(2):186-95
52. Specchia G, Pastore D, Carluccio P, et al. Gemtuzumab ozogamicin with cytarabine and mitoxantrone as a third-line treatment in a poor prognosis group of adult acute myeloid leukemia patients: a single-center experience. Ann Hematol 2007;86(6):425-8
53. Piccaluga PP, Martinelli G, Rondoni M, et al. First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients. Leuk Res 2004;28(9):987-90
54. Tsimberidou AM, Estey E, Cortes JE, et al. Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia. Cancer Chemother Pharmacol 2003;52(6):449-52
55. Burnett AK, Kell WJ, Goldstone AH, et al. The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: preliminary analysis of 1115 patients in the MRC AML15 Trial. Blood 2006;108(11):[abstract#13] •• This preliminary analysis of 1115 patients randomized in the MRC AML15 trial indicates that the addition of GO to induction chemotherapy can reduce the relapse risk without adding significant extra toxicity and this has significantly improved the disease-free survival in the GO arm.
56. Available from: http://www.cancer.gov/clinicaltrials/
57. www.ClinicalTrials.gov, Identifier: NCT00070174
58. www.ClinicalTrials.gov, Identifier: NCT00372593
59. Paietta E. Expression of cell-surface antigens in acute promyelocytic leukaemia. Best Pract Res Clin Haematol 2003;16(3):369-85
60. Takeshita A, Shinjo K, Naito K, et al. Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells. Leukemia 2005;19(8):1306-11
61. Lo-Coco F, Cimino G, Breccia M, et al. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood 2004;104(7):1995-9
62. Petti MC, Pinazzi MB, Diverio D, et al. Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg CMA-676). Br J Haematol 2001;115(1):63-5
63. Estey EH, Giles FJ, Beran M, et al. Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood 2002;99(11):4222-4
64. Tsimberidou AM, Estey E, Whitman GJ, et al. Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies. Leuk Res 2004;28(9):991-4
65. Aribi A, Kantarjian HM, Estey EH, et al. Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia. Cancer 2007;109(7):1355-9
66. Giles FJ, Cortes JE, Halliburton TA, et al. Intravenous corticosteroids to reduce gemtuzumab ozogamicin infusion reactions. Ann Pharmacother 2003;37(9):1182-5
67. Wadleigh M, Richardson PG, Zahrieh D, et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 2003;102(5):1578-82
68. Giles FJ, Kantarjian HM, Kornblau SM, et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 2001;92(2):406-13
69. Bearman SI. Veno-occlusive disease of the liver. Curr Opin Oncol 2000;12(2):103-9
70. Giles F, Estey E, O'Brien S. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer 2003;98(10):2095-104
71. Rajvanshi P, Shulman HM, Sievers EL, McDonald GB. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood 2002;99(7):2310-4
72. McDonald GB. Management of hepatic sinusoidal obstruction syndrome following treatment with gemtuzumab ozogamicin (Mylotarg). Clin Lymphoma 2002;2(Suppl 1):S35-9
73. McKoy JM, Angelotta C, Bennett CL, et al. Gemtuzumab ozogamicin- associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res 2007;31(5):599-604
74. Versluys B, Bhattacharaya R, Steward C, et al. Prophylaxis with defibrotide prevents veno-occlusive disease in stem cell transplantation after gemtuzumab ozogamicin exposure. Blood 2004;103(5):1968
75. European Medicines Agency. Public summary of positive opinion for orphan designation of gemtuzumab ozogamicin for the treatment of acute myeloid leukaemia. 2004. Available from: www.emea.europa.eu/pdfs/human/comp/opinion/ 037504en.pdf [Last accessed 21 January 2008]
76. European Medicines Agency. Questions and answers on recommendation for the refusal of the marketing authorisation for Mylotarg. 2007. Available from: www.emea.europa.eu/pdfs/human/ opinion/31855307en.pdf [Last accessed 21 January 2008]
77. Leopold LH, Willemze R. The treatment of acute myeloid leukemia in first relapse: a comprehensive review of the literature. Leuk Lymphoma 2002;43(9):1715-27
78. Amico D, Barbui AM, Erba E, et al. Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitto: role of Chk1 and Chk2 phosphorylation and caspase 3. Blood 2003;101(11):4589-97